A practical reference on anti-doping testing: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-08-30 and is reviewed periodically as new material appears.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human use | Investigational status in most countries |
| Sports status | Prohibited by WADA | Classified as non-approved or metabolic modulator |
| Common analytical method | LC-MS/MS | Used for trace detection in biological samples |
| Typical test matrices | Urine and blood | Sample choice depends on testing program |
| Human trial data | None published | Effects and safety are not established |
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
=== Other drugs === Other drugs like sulfur and resorcinol have also been found useful in treating seborrheic dermatitis. These drugs have keratolytic and antiseptic properties which may benefit seborrhoea. Salicylic acid has a mild effect on seborrhoea.
=== 1961 === January 3: President Eisenhower severs diplomatic relations with Cuba. January 13: Patrice Lumumba, elected President of the Republic of the Congo (Léopoldville) is assassinated with the support of the CIA in the context of the Congo Crisis January 20: John F. Kennedy becomes President of the United States. January 31: Ham is launched into space as a part of Project Mercury, a mission to successfully place a human into orbit and return them safely. February 4: Angolan nationalists, including communists, begin an insurgency against Portuguese rule. This marked the beginning of the Portuguese Colonial War. February 12: Venera 1 is successfully launched by the Soviet Union with the intention of conducting a flyby mission to Venus. April 12: Yuri Gagarin becomes the first human in space and first to orbit the Earth when the Soviet Union successfully launches Vostok 1. April 17–19: Bay of Pigs Invasion: A CIA-backed invasion of Cuba by counter-revolutionaries ends in failure. April 21: Sierra Leone becomes independent from the UK under Commonwealth status. May 5: Alan Shepard becomes the first American to go into space when Freedom 7 is launched successfully. May 19: Venera 1 successfully reaches Venus being the first spacecraft to do so, but is unable to transmit any data. May 25: John F. Kennedy announces the US intention to put a man on the Moon – kickstarting Project Mercury, America's first human spaceflight program. June 4: Kennedy meets with Khrushchev in Vienna.
Keratoglobus is a very rare condition that causes corneal thinning primarily at the margins, resulting in a spherical, slightly enlarged eye. It may be genetically related to keratoconus. Pellucid marginal degeneration causes thinning of a narrow (1–2 mm) band of the cornea, usually along the inferior corneal margin. It causes irregular astigmatism that, in the early stages of the disease can be corrected by spectacles. Differential diagnosis may be made by slit-lamp examination. Posterior keratoconus, a distinct disorder despite its similar name, is a rare abnormality, usually congenital, which causes a nonprogressive thinning of the inner surface of the cornea, while the curvature of the anterior surface remains normal. Usually only a single eye is affected. Post-LASIK ectasia is a complication of LASIK eye surgery.
Sources: en.wikipedia.org
Susan M Gaines is an American writer. She is the author of the novels Accidentals (2020) and Carbon Dreams (2001), and co-author with Geoffrey Eglinton and Jurgen Rullkötter of the science book Echoes of Life: What Fossil Molecules Reveal about Earth History (2009). Her short stories have been nominated twice for the Pushcart Prize. She is a former fellow of the Hanse Institute for Advanced Study in Germany. In 2018, she was awarded a Suffrage Science Award for women in science and science writers who have inspired others.
Frank Edward Bryan. Lately Chair, Belfast Metropolitan College. For services to Further Education and the Economy in Northern Ireland. James Maurice Bullick. Finance and Compliance Director and Honorary Treasurer, Belfast Harbour Commissioners and British Ports Association. For services to the Maritime Industry. Professor Emma Bunce. Professor of Planetary Plasma Physics, University of Leicester. For services to Astronomy and Science Education. Paul Jeffrey Burger. Founder and Partner, Soho Artists. For services to the Music Industry and to Charity. Ruth Catherine Margaret Busby. People and Transformational Director, Great Western Railway and Network Rail Wales and Western. For services to Diversity in the Rail Industry. Lorraine Suzette Bushell. For services to Estranged Grandparents. Dr. Samantha Jane Callan. Director and Co-Founder, The Family Hubs Network Ltd. For services to Victims of Domestic Abuse. Eunice Fay Campbell-Clark. Lately Member, City of Nottingham Council. For services to Local Government. Dr. Kathryn Myrtle Chamberlain. Lately Chief Executive, Independent Monitoring Authority for the Citizens Rights' Agreements. For Public Service. Denise Joan Christie. Chair, Elizabeth Casson Trust. For services to Occupational Therapy. Jayne Louise Clarke. Executive Principal, Pinnacle Learning Trust. For services to Further Education. The Reverend Anthony James Collins. For services to Healthcare and to the community in Harrogate and Ripon, North Yorkshire. Neil Ernest Alexander Constable. Lately Chief Executive Officer, Shakespeare's Globe. For services to Theatre.
Under CLIA, anyone, including patients and their families, laboratory personnel, and the general public, can submit anonymous complaints if there are concerns about the quality of laboratory testing. The most common CLIA complaints are concerns about a laboratory's operations, such as: unlabeled specimens, unqualified staff, record falsification, missing or incorrect test results and the confidentiality of patient information. For laboratories accredited by a laboratory Accreditation Organization (AO), complaints may be referred to the laboratory's AO. Though anyone may lodge a complaint, relatively few laboratory complaints have been filed. This may be due to a lack of publicity about complaint filing, since CLIA does not require that laboratory employees or patients be made aware of how to file a complaint, and to privacy concerns stemming from the lack of whistleblower protections. Other limiting factors include an increasing reliance on on-the-job (OTJ)- trained lab personnel who are unaware of regulatory requirements, foreign-sponsored H1b medical technologists fearing retaliatory deportation, and an aging workforce awaiting retirement. Laboratory whistleblowers may face countermeasures such as cover-ups, loss of income, position, or employment, punitive lawsuits, and attacks on their reputation, which would degrade their living conditions and dissuade them from bringing fraud to light. A June 2006 GAO report found that lab workers may file complaints infrequently due to concerns about retaliation and a lack of understanding of how to do so.
Sources: en.wikipedia.org
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.
Sports authorities prohibit it because it is not approved for human use and has potential performance-enhancing effects. It appears on anti-doping lists under non-approved or metabolic modulator categories.
Detection usually uses liquid chromatography-tandem mass spectrometry. The method targets the parent compound or its metabolites in urine or blood.
Legality depends on the country and the intended use. In many places it is not approved as a medicine and may be sold only as a research chemical. Importation or possession can be restricted, and sports organizations prohibit it.